Behold the Dangers of a One-Trick Pony: Affymax, Inc. (AFFY) and More

Page 1 of 2

At the end of last year, I proclaimed Omontys — an erythropoiesis-stimulating agent, or ESA, that aids in the formation of red blood cells — as one of my 10 drugs approved by the Food and Drug Administration in 2012 to be thankful for. The drug, developed by Affymax, Inc.(NASDAQ:AFFY) and Takeda Pharmaceutical Company Limited, was designed to be a once-a-month injectable treatment for patients on dialysis with chronic kidney disease. Today, it’s the straw that broke Affymax shareholders’ back.

Affymax, Inc. (NASDAQ:AFFY)On Saturday, Affymax and Takeda, in cooperation with the FDA, announced the voluntary recall of all lots of injectable Omontys. According to the release, more than 25,000 patients have received the anemia drug since it launched, with 0.2% of them responding with a hypersensitivity reaction that — in a third of those patients — led to anaphylaxis. Fatal reactions were reported in 0.02% of all cases where Omontys was administered.

Houston, we have a problem.

For Takeda, the blow isn’t as severe, as it’s a large pharmaceutical company with dozens of partnerships. For Affymax, this is a completely different story.

In its third-quarter results, released in November, Affymax noted Omontys sales of just $15 million — it wasn’t exactly selling like hotcakes to begin with — and noted at the time that the company wouldn’t be receiving any further milestone or profit equalization payments from Takeda for 2012. Moving forward, it’s not going to be receiving anything as Omontys is Affymax’s only approved drug. Keep in mind that operating expenses including stock-based compensation were guided to a whopping $130 million to $135 million last quarter, and it boasts just $100 million in cash and investments.

OK… breathe… Affymax had to have thought this through and clearly has other compounds in its pipeline, right? That’d be wishful thinking because it only has two other compounds in clinical trials: a late-stage conversion study on — you guessed it — Omontys for use as a once-a-week ESA as opposed to three times a week, and a mid-stage study outside of the U.S. utilizing Omontys to treat dialysis and non-dialysis related anemia for patients with pure red cell aplasia.

(Bangs head on table)

It gets even worse. Let’s assume for a moment that Affymax and Takeda are able to work out these not-so-minor kinks with Omontys to the FDA’s satisfaction — it’ll still be giving Amgen, Inc. (NASDAQ:AMGN) even more time to further its market share lead. Amgen, which makes Epogen — the leading anemia treatment for the past two decades – fortified its market-leading spot a while ago by signing multi-year dialysis center agreements with DaVita HealthCare Partners Inc (NYSE:DVA) and Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS). They’re arguably the two biggest names in dialysis, as my Foolish colleague Brandy Betz noted last month. While this doesn’t negate Affymax from dealing with DaVita and Fresenius, it makes orchestrating an agreement far less likely.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!